Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1
Brief Summary: The purpose of this study is to assess the safety and efficacy of brodalumab taken every two weeks at two different doses.


Options:
A: Arm Label: Secukinumab 150mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 150 mg s.c. | Arm Label: Secukinumab 300mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300 mg s.c. | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Secukinumab 150 mg s.c.; Assigned to Arm(s): Secukinumab 150mg | Intervention Type: DRUG; Name: Secukinumab 300 mg s.c.; Assigned to Arm(s): Secukinumab 300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab, Drug: placebo | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 140 mg brodalumab, 210 mg brodalumab, placebo
C: Arm Label: Apremilast 10mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 10mg | Arm Label: Apremilast 20mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo/Apremilast 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Placebo/Apremilast 30mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 10mg; Assigned to Arm(s): Apremilast 10mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Apremilast 20mg | Intervention Type: DRUG; Name: Apremilast 30 mg; Assigned to Arm(s): Apremilast 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Apremilast 30mg; Assigned to Arm(s): Placebo/Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Placebo/Apremilast 20 mg
D: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: placebo for ustekinumab | Arm Label: Ustekinumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: ustekinumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for ustekinumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Ustekinumab (Part A) | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for ustekinumab; Assigned to Arm(s): Placebo (Part A), Risankizumab (Part A)

Answer: B